Abstract
Temozolomide (TMZ) is a monofunctional methylating agent which is spontaneously activated in aqueous solution into the dacarbazine metabolite 5-(3-methyl-1-triazeno)imidazole-4-carboxamide. This drug has been approved for the treatment of metastatic melanoma and glioblastoma multiforme, the latter in combination with radiotherapy. Furthermore, clinical trials have been performed to assess the activity of TMZ, alone or in combination, on brain metastatic solid tumors and leukaemias. This review will report clinical evidence on the use of TMZ for the treatment of different types of cancer; it also considers current knowledge on TMZs molecular mechanisms of action of and discusses relevant patents relating to the same drug.
Keywords: Anti-cancer drug, alkylating drug, DNA damage, temozolomide, triazenes
Recent Patents on Anti-Cancer Drug Discovery
Title: The Use of Temozolomide for the Treatment of Malignant Tumors: Clinical Evidence and Molecular Mechanisms of Action
Volume: 5 Issue: 3
Author(s): Roberto Bei, Laura Marzocchella and Mario Turriziani
Affiliation:
Keywords: Anti-cancer drug, alkylating drug, DNA damage, temozolomide, triazenes
Abstract: Temozolomide (TMZ) is a monofunctional methylating agent which is spontaneously activated in aqueous solution into the dacarbazine metabolite 5-(3-methyl-1-triazeno)imidazole-4-carboxamide. This drug has been approved for the treatment of metastatic melanoma and glioblastoma multiforme, the latter in combination with radiotherapy. Furthermore, clinical trials have been performed to assess the activity of TMZ, alone or in combination, on brain metastatic solid tumors and leukaemias. This review will report clinical evidence on the use of TMZ for the treatment of different types of cancer; it also considers current knowledge on TMZs molecular mechanisms of action of and discusses relevant patents relating to the same drug.
Export Options
About this article
Cite this article as:
Bei Roberto, Marzocchella Laura and Turriziani Mario, The Use of Temozolomide for the Treatment of Malignant Tumors: Clinical Evidence and Molecular Mechanisms of Action, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (3) . https://dx.doi.org/10.2174/157489210791760526
DOI https://dx.doi.org/10.2174/157489210791760526 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
NBN Polymorphysms and Cancer Susceptibility: A Systematic Review
Current Genomics Editorial [Hot Topic: Novel and Emerging Drugs for Leukemias (Guest Editor: Tadeusz Robak)]
Current Cancer Drug Targets Transcriptome and Proteome Analyses of Drug Interactions with Natural Products
Current Drug Metabolism Hybrid Pharmacophore Design and Synthesis of Naphthalimide– Benzimidazole Conjugates as Potential Anticancer Agents
Letters in Drug Design & Discovery Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design The Link Between Conventional and Novel Anti-Cancer Therapeutics with Thrombotic Microangiopathy
Drug Metabolism Letters Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Humoral Immunity in HIV-1 Exposure: Cause or Effect of HIV Resistance?
Current HIV Research Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy Invasive Aspergillosis: New Insights into Disease, Diagnostic and Treatment
Current Pharmaceutical Design Antineoplastic Activities, Apoptotic Mechanism of Action and Structural Properties of a Novel Silver(I) Chelate
Current Medicinal Chemistry Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia
Current Drug Targets Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Chemomodulating Effects of Flavonoids in Human Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism Targeting EZH2 for Cancer Therapy: Progress and Perspective
Current Protein & Peptide Science Pulmonary Arterial Hypertension
Current Vascular Pharmacology Radiation Protection of the Child from Diagnostic Imaging
Current Pediatric Reviews Safety Concerns Related to Hematopoietic Stem Cell Gene Transfer Using Retroviral Vectors
Current Gene Therapy